藥品名稱
drug name | Levocetirizine (Xyzal / Levozine(舊名), 驅異樂膜衣錠) 5 mg/tab |
| 藥檔狀態 | 使用中 |
成 份
Ingredient | Levocetirizine dihydrochloride |
| 單位含量 | 5 mg/tab |
| Dosage Forms | Film-coated tablet: 5 mg |
| 外觀描述 | 橢圓形 白色 口服/錠劑 |
| Appearance | oval white oral/tablet |
標 示
outward | Y |
廠商名稱
Manufacturer | 荷商葛蘭素史克藥廠股份有限公司台灣分公司 |
製 造 商
Manufacturer | UCB FARCHIM S.A., SWITZERLAND |
字 號
Product ID | 衛署藥輸字第023792號 |
藥理分類
Pharmacologic Category | Respiratory Agents/ Antihistamines/ Non-Sedation |
作用機轉
Mechanism of action | Levocetirizine is an antihistamine which selectively competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. Levocetirizine, the active enantiomer of cetirizine, has twice the binding affinity at the H1-receptor compared to cetirizine. |
| 用途/適應症 | 抗組織胺,緩解過敏之各種症狀 |
| Use |
Treatment of symptoms associated with allergic conditions such as seasonal allergic rhinitis and perennial allergic rhinitis
|
衛福部核准適用症狀
MOHW approved indications |
治療成人及六歲以上孩童因過敏性鼻炎、慢性蕁麻疹等所引起的各種過敏徵狀。
|
| Dose |
Administration: Oral
【Adult】:
5 mg QD (in the evening); some patients may experience relief of symptoms with 2.5 mg QD
In one clinical trial, the titrated use of higher doses (up to 10 mg QD ) in adults demonstrated clinical improvement (Staevska 2010).
【Geriatric】:
Refer to adult dosing; dosing should begin at the lower end of the dosing range.
【Pediatric】:
6 months to 5 years: 1.25 mg QD (in the evening); max: 1.25 mg
6-11 years: 2.5 mg QD (in the evening); max: 2.5 mg/day
≧12 years: 5 mg QD (in the evening); some patients may experience relief of symptoms with 2.5 mg QD
【Dosage Adjustment in Renal Impairment】:
6 months to 11 years with renal impairment: Contraindicated.
≧12 & Adults:
Clcr 50-80 mL/min: 2.5 mg QD
Clcr 30-50 mL/min: 2.5 mg QOD
Clcr 10-30 mL/min: 2.5 mg BIW (every 3 or 4 days)
Clcr <10 mL/min, HD patients: Contraindicated
|
懷孕分級
Pregnancy Risk Factor |
B
Lactation:Enters breast milk/not recommended
|
| 禁忌症 |
1.對levocetirizine、cetirizine、hydroxyzine、piperazine衍生物過敏，或對本藥中任何成分過敏者。
2.需要透析治療的末期腎臟疾病病人(eGFR < 15 ml/min)。
|
| Contraindications |
Known hypersensitivity to levocetirizine, cetirizine, or any component of the formulation; end-stage renal disease (CrCl <10 mL/minute); hemodialysis
|
| 常見副作用 | 昏昏欲睡，口乾，胃痛或噁心 |
| Common adverse drug reactions | sleepy, dry mouth, stomachach or nausea |
| Adverse Reactions |
>10%:
Gastrointestinal: Diarrhea (children 4% to 13%)
1% to 10%:
Central nervous system: Drowsiness (2% to 6%), fatigue (1% to 4%)
Gastrointestinal: Constipation (children 7%), vomiting (children 4%), xerostomia (2% to 3%)
Neuromuscular & skeletal: Weakness (2%)
Otic: Otitis media (children 3%)
Respiratory: Nasopharyngitis (4% to 6%), cough (children 3%), epistaxis (children 2%), pharyngitis (1% to 2%)
Miscellaneous: Fever (children 4%)
<1% (Limited to important or life-threatening): Aggressive behavior, agitation, anaphylaxis, angioedema, dysuria, fixed-drug eruption, hepatitis, hypersensitivity, increased serum bilirubin, increased serum transaminases, movement disorder (including dystonia and oculogyric crisis), myalgia, nausea, palpitations, paresthesia, pruritus, skin rash, seizure, suicidal ideation, syncope, urinary retention, urticaria, visual disturbances, weight gain
|
監測
Monitoring |
Creatinine clearance (prior to treatment for dosing adjustment)
|
| 警語與注意事項 | 酒精性飲料可能加重嗜睡。1130730換廠為"UCB FARCHIM S.A."。 |
| Warnings & precautions | |
| 針劑溶解條件 |
|
| 針劑稀釋條件 |
|
| 針劑不相容性 |
|
| 針劑施打條件 |
|
| 針劑保存安定性 |
室溫儲存。
|
最近修改日期時間
Updated | 7/30/2024 10:38:16 AM |
|
現用藥品
Available
|
停用藥品
Old item
|
|
衛福部仿單連結
DrugLabelingURL
|
二維條碼
QR code
|
|